Home> Products> Inhibitors> Ceftaroline fosamil-CAS 400827-46-5
price inquiry for CAS:400827-46-5, Product:Ceftaroline fosamil

Ceftaroline fosamil CAS: 400827-46-5

Category: Inhibitors
Product Name: Ceftaroline fosamil
Cat No: I000042
CAS No: 400827-46-5
Related CAS: 229016-73-3
Synonyms: Teflaro; Zinforo
Molecular Formula: 684.68
Molecular Weight: C22H21N8O8PS4
SMILES: O=C(C(N12)=C(SC3=NC(C4=CC=[N+](C)C=C4)=CS3)CS[C@]2([H])[C@H](NC(/C(C5=NSC(NP(O)(O)=O)=N5)=N\OCC)=O)C1=O)[O-]
InChI: InChI=1S/C22H21N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37)/b26-13-/t14-,19-/m1/s1
InChIKey: ZCCUWMICIWSJIX-NQJJCJBVSA-N
CAS 400827-46-5,Ceftaroline fosamil
  • Description

Ceftaroline fosamil, also known as TAK 599 and PPI 0903, is an advanced-generation cephalosporin antibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.

  • Spec

Purity: >95%

  • References


1:Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ.Int J Infect Dis. 2017 Apr;57:27-31. doi: 10.1016/j.ijid.2017.01.019. Epub 2017 Jan 25. PMID: 28131729 Free Article
2:Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review. El Hajj MS, Turgeon RD, Wilby KJ.Int J Clin Pharm. 2017 Feb;39(1):26-32. doi: 10.1007/s11096-016-0417-z. Epub 2017 Jan 5. PMID: 28058593
3:Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application. Yim J, Molloy LM, Newland JG.Infect Dis Ther. 2017 Mar;6(1):57-67. doi: 10.1007/s40121-016-0144-8. Epub 2016 Dec 30. Review. PMID: 28039666 Free PMC Article
4:Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ.Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02015-16. doi: 10.1128/AAC.02015-16. Print 2017 Feb. PMID: 27895012
5:Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Scott LJ.Drugs. 2016 Nov;76(17):1659-1674. Review. PMID: 27766567
6:A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J.J Antimicrob Chemother. 2016 Dec;71(12):3575-3584. Epub 2016 Sep 1. PMID: 27585969 Free PMC Article
7:Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study. Athans V, Kenney RM, Wong J, Davis SL.J Antimicrob Chemother. 2016 Dec;71(12):3568-3574. Epub 2016 Aug 15. PMID: 27530754
8:Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS.J Clin Pharmacol. 2017 Mar;57(3):345-355. doi: 10.1002/jcph.809. Epub 2016 Sep 27. PMID: 27510635
9:Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D.J Antimicrob Chemother. 2016 Jun;71(6):1748-9. doi: 10.1093/jac/dkw136. Epub 2016 Apr 13. No abstract available. PMID: 27076104
10:Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, Zeitlinger M.Antimicrob Agents Chemother. 2016 May 23;60(6):3617-25. doi: 10.1128/AAC.00097-16. Print 2016 Jun. PMID: 27044549 Free PMC Article


price inquiry for CAS:400827-46-5, Product:Ceftaroline fosamil